Henlius' HLX15 (biosimilar- daratumumab) Receives IND Approval for Multiple Myeloma in China
Shots:
- Henlius reported that NMPA has approved the IND application of HLX15 for the treatment of multiple myeloma
- The company has compared HLX15 in a head to head study with reference daratumumab via analytical & preclinical studies. The results demostrated that HLX15 is highly similar to reference daratumumab
- The company has developed the HLX15 in accordance with the Technical Guidelines of Development and Evaluation of Biosimilar Drugs & EMA Guideline on Similar Biological Medicinal Products
Click here to read full press release/ article
Ref: Henlius | Image: Henlius
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com